The 7th Annual Cell Engager Summit covers topics such as:
- A Novel Class of NK-cell Engagers for Tumor Targeting
- Analyzing Target Selection to Maximize Efficacy Whilst Minimizing Toxicity
- Humabody® VH as T-cell Enhancing Therapeutics for Immuno Oncology
- The ImmTACTM Platform: Progress and Clinical Insight from the Soluble TCR-based Bispecific Approach
- Reducing Key Toxicities with T Cell Engaging Bispecifics
- The Promise of Next Generation T Cell Engagers for Cancer Treatment
- Omid Vafa
- A Novel Multispecific T Cell Engager Platform for a Better Therapeutic Window
- Rational Combinations for Bispecific T-cell Engager (BiTE®) Immune Therapy in Solid Tumors
- Prevention and Treatment of CRS with Bispecific Antibodies
- Mechanisms of Bispecific T cell Engager Efficacy and Toxicity in Murine Tumor Models
- Focusing on Dosing Regimens and the Therapeutic Window in order to Develop Easily Administered Drugs
The 7th Annual Cell Engager Summit might be held in Boston, United States in 2025.
